Expression of ABC Efflux Transporters in Placenta from Women with Insulin-Managed Diabetes

Gregory J. Anger¹*, Alex M. Cressman¹,²*, Micheline Piquette-Miller¹,²

¹Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada, ²Department of Pharmacology and Toxicology, Faculty of Medicine, University ofToronto, Toronto, Ontario, Canada

Abstract
Drug efflux transporters in the placenta can significantly influence the materno-fetal transfer of a diverse array of drugs and other xenobiotics. To determine if clinically important drug efflux transporter expression is altered in pregnancies complicated by gestational diabetes mellitus (GDM-I) or type 1 diabetes mellitus (T1DM-I), we compared the expression of multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2) and the breast cancer resistance protein (BCRP) via western blotting and quantitative real-time polymerase chain reaction in samples obtained from insulin-managed diabetic pregnancies to healthy term-matched controls. At the level of mRNA, we found significantly increased expression of MDR1 in the GDM-I group compared to both the T1DM-I (p<0.01) and control groups (p<0.05). Significant changes in the placental protein expression of MDR1, MRP2, and BCRP were not detected (p>0.05). Interestingly, there was a significant, positive correlation observed between plasma hemoglobin A1c levels (a retrospective marker of glycemic control) and both BCRP protein expression (r = 0.45, p<0.05) and BCRP mRNA expression (r = 0.58, p<0.01) in the insulin-managed DM groups. Collectively, the data suggest that the expression of placental efflux transporters is not altered in pregnancies complicated by diabetes when hyperglycemia is managed; however, given the relationship between BCRP expression and plasma hemoglobin A1c levels it is plausible that their expression could change in poorly managed diabetes.

Introduction
Over 220 million people worldwide are diagnosed with diabetes and rising prevalence is reported in nearly all surveyed populations [1,2]. Accordingly, the percentage of pregnancies affected by pre-existing type 1 (T1DM) and type 2 diabetes mellitus (T2DM) or by diabetes that develops during the second and third trimesters of pregnancy, called gestational diabetes mellitus (GDM), is also on the rise. In the context of pharmacokinetic variation, it is known that diabetes alters drug-disposition mechanisms in non-pregnant subjects, as reviewed by Gwilt and colleagues [3], but the impact of diabetes on drug disposition in pregnancy has not been thoroughly evaluated. Atypical drug disposition in pregnancy has implications for both maternal and fetal health, as the effectiveness of clinically important therapeutics may be compromised.

Drugs, xenobiotics, and their metabolites encounter a variety of epithelial and endothelial barriers as they make their way to their site(s) of action and elimination. To circumvent these barriers, they are required to cross cell membranes. Multidrug resistance protein (MDR) 1 (P-glycoprotein; Gene: ABCB1), multidrug resistance-associated protein 2 (MRP2; Gene: ABCC2) and the breast cancer resistance protein (BCRP; Gene: ABCG2) are abundantly expressed ATP-binding cassette (ABC) drug efflux transporters found in the apical localization of the placental syncytiotrophoblast layer (Fig. 1). Here they limit the materno-fetal transfer of a diverse array of drug substrates by the ATP-driven efflux of substrates from the fetal compartment into the maternal circulation [4,5,6]. The importance of these transporters in determining fetal xenobiotic exposure has been well-established in placental cell lines and placental primary cultures [7], in mutant/knockout mice [8,9,10,11], and in ex vivo placental perfusion models [12,13,14]. In one such study, relative to controls, pregnant Mdr1 gene knockout mice (Mdr1−/− mice) treated with the Mdr1/BCrp-specific inhibitor GF120918 exhibited twice the fetal penetration of the Mdr1/BCrp substrate topotecan, a DNA topoisomerase inhibitor and potent antineoplastic agent [6]. Whereas lack of or decreased expression can lead to increased exposure to xenobiotics, over expression may result in decreased exposure. This may result in clinical consequences when treating fetal illness (e.g. fetal arrhythmias with digoxin, a MDR1 substrate) or by limiting the maternal-fetal passage of therapeutic agents [6]. Whereas lack of or decreased expression can lead to increased exposure to xenobiotics, over expression may result in decreased exposure. This may result in clinical consequences when treating fetal illness (e.g. fetal arrhythmias with digoxin, a MDR1 substrate) or by limiting the maternal-fetal passage of therapeutics believed to contribute to the prevention of vertical disease transmission (e.g. highly active antiretroviral therapy in antenatal HIV infection).

We have previously demonstrated that placental MDR1, MRP2 and BCRP mRNA expression is elevated in rat dams with streptozotocin-induced gestational diabetes mellitus (GDM) but nearly normal in rat dams with streptozotocin-induced GDM whose blood glucose was normalized following insulin treatment...
Maternal blood  

\[ \text{MDR1} \quad \text{MRP2} \quad \text{BCRP} \]  

Fetal blood

Figure 1. Localization of MDR1, MRP2, and BCRP in placenta. The syncytiotrophoblast (S) layer of the placenta is comprised of multinucleated (N) cells that contain a number of apically-localized transport proteins that contribute to the function of the placental barrier, including MDR1, MRP2, and BCRP. doi:10.1371/journal.pone.0035027.g001

[16]. In the aforementioned study, relative to controls, fetal exposure to the MDR1 substrate lopinavir, a commonly used HIV protease inhibitor, was found to be dramatically lower in rat dams with streptozotocin-induced GDM [16]. These profound results and the increasing prevalence of diabetes mellitus in pregnancy prompted us to study the impact of GDM and T1DM on placental transporter expression.

Therefore, in the present study, we examined mRNA and protein expression of MDR1, MRP2 and BCRP in placentas from pregnancies complicated by type 1 diabetes mellitus (T1DM-I) or gestational diabetes mellitus (GDM-I). All available placental samples were obtained from patients whose glycemia was managed with insulin treatment. We hypothesized that placental drug efflux transporter expression may be altered in individuals who have diabetes, but could be normalized to levels found in healthy term controls in patients with well-managed diabetes based on our previous preclinical findings in pregnant animal models of non-treated and insulin-treated diabetes mellitus [16].

Methods

Sample Acquisition

Thirty-five human specimens from pregnancies meeting our inclusion/exclusion criteria (Table 1) were obtained by the Research Centre for Women’s and Infants’ Health (RCWIH) Biobank program of Mount Sinai Hospital, in accordance with the policies of the Mount Sinai Hospital Research Ethics Board. Sample acquisition and aspects of placental processing and measurement are extensively described on the RCWIH Biobank’s website: http://biobank.lunenfeld.ca. Briefly, immediately after delivery, large tissue cores through the full thickness of the placenta were obtained in each quadrant, avoiding chorionic plate tissue and areas with obvious evidence of thrombosis or other abnormalities. Samples were snap-frozen in liquid nitrogen and stored at \(-80 ^\circ C\) until use. All clinical data that was extracted from patient charts and collected by the RCWIH Biobank program of Mount Sinai Hospital was made available to this study. In accordance with the recommendations of Nelson and Burton [17], supplemental tables describing key patient variables were compiled (See data S1). Extensive chart review was completed to ensure that all patients met our inclusion/exclusion criteria and that any medications patients were taking were recorded. Samples included in this study reflect total RCWIH Biobank availability between September 2006 and February 2012: 8 T1DM-I samples, 13 GDM-I samples, and 14 randomly selected term controls.

Hemoglobin A1c Level Determination

HbA1c levels were determined by GLP certified laboratories using the Roche Cobas Integra Clinical Chemistry System. In this assay, all hemoglobin variants which are glycated at the \(\beta\)-chain \(N\)-terminus and which have antibody-recognizable regions identical to that of HbA1c are determined. HbA1c is presented as a percentage of total hemoglobin (% HbA1c).

RNA Extraction and cDNA Synthesis

Total RNA was extracted from 60 mg of placental tissue using the TRizol method (Invitrogen, Carlsbad, CA) and subjected to qualitative and quantitative measurements (\(A_{260}/280>1.90\) and \(A_{280}/320>1.60\)) using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA). 4 \(\mu\)L of total extracted RNA was reverse transcribed to cDNA using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (MBI Fermentas, Hanover, MD), all according to the manufacturer’s instructions. Briefly, 4 \(\mu\)L of reaction mix (containing reaction buffer, dNTPs, oligo and random hexamer primers), 2 \(\mu\)L of Maxima Enzyme mix containing Maxima Reverse Transcriptase and RiboLock RNase inhibitor, sample RNA, and nuclease-free \(H_2O\) were added and centrifuged. Samples were then reverse-transcribed in an Eppendorf Thermocycler (Eppendorf AG, Hamburg, Germany) with the following thermocycling parameters: 10 min at 25°C, 30 min at 50°C, and 5 min at 85°C.

Real-Time Quantitative Polymerase Chain Reaction (qPCR)

MDR1 (ABCB1), MRP2 (ABCC2), and BCRP (ABCG2) mRNA expression levels in placenta from T1DM-I, GDM-I, and term-matched controls were determined by real-time quantitative reverse-transcriptase polymerase chain reaction. RT-qPCR was performed on cDNA using LightCycler technology with SYBR Green I fluorescence detection (Roche Diagnostics, Montreal, QC). PCR oligonucleotides were synthesized at The Hospital for Sick Children (DNA Synthesis Centre, Toronto, ON) and were designed to span adjacent exon-exon junctions to eliminate the amplification of genomic DNA. Primer sequences were as follow: 5’-ACCAGATAAAAAAGAGAGGTTGCAACGGG-3’ (MDR1-F), 5’-TCCCCGGCGCCGGTGTGCAC-3’ (MDR1-R), 5’-AGCAGCCATAGACTTGGCTGCCCTT-3’ (MRP2-F), 5’-AGCAAAACGAGGACCATGTGCC-3’ (MRP2-R), 5’-AGCAGCTTCCTCGTTGCAACA-3’ (BCRP-F), 5’-GGTGACACCTTGGAGCTTGGCCACT-3’ (BCRP-R), 5’-AGGTTCCAGGTGCTTGGCAGGACCGTT-3’ (\(\beta\)-actin-F), and 5’-AGCACATCGGACGAGCTTGGCAG-3’ (\(\beta\)-actin-R). Briefly, 2 \(\mu\)L of cDNA was added to 18 \(\mu\)L of reaction mix containing 4 \(\mu\)L of Roche SYBR green, 100pmol of forward and reverse qPCR primers, and nuclease-free \(H_2O\). Sequences were amplified using the following thermocycling parameters: 1 cycle of 10 min at 95°C, 50 cycles (6 seconds at 95°C, 5 seconds at 55°C, and 6 seconds at 72°C), followed by a continuous 150-second melt curve from 65-99°C. A melt-curve was used after amplification to ensure primer specificity such that all samples exhibited a single amplicon. No template control samples were also run to confirm
that samples and primers were not contaminated with any genomic DNA.

Expression levels of transporters and β-actin mRNA as Cq (the point at which gene of interest and reference gene could be quantified) were quantified using the Roche LightCycler II software (Ver. 3.5) configured with the Roche LightCycler II real-time qPCR instrument (Roche Diagnostics GmbH, Hamburg, Germany). Gene-of-interest expression was normalized to β-actin (ACTB) mRNA expression, using the efficiency-corrected ΔCt method and presented as a gene-to-β-actin ratio. The efficiency-corrected ΔCt method was used because there were slight differences in the efficiencies of our primer sets as determined by standard curve analysis of serially-diluted calibrator cDNA. Gene-to-β-actin ratios were then converted to percentages of a calibrator sample and presented as such in figure 2.

### Western Blotting

300 mg of placental samples were homogenized using a motorized pestle in radioimmunoprecipitation assay (RIPA) buffer, containing freshly added dithiothrietol (1 mM; DTT; Sigma-Aldrich, Oakville, ON), phenylmethylsulfonl fluoride (0.5 mM; PMSF; BioShop Canada Inc., Burlington, ON) and 1X protease inhibitor cocktail (Sigma-Aldrich, Oakville, ON). Homogenates were then incubated on ice for 30 min with brief vortex mixing at 15 min and subsequently centrifuged at 18,000 g for 15 min. For each sample, the supernatant was isolated and subjected to a Bradford assay [18]. Samples containing 60 μg of protein in Laemmli sample loading buffer were heated at 36°C for 20 min and then separated via 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories Canada, Ltd., Mississauga, ON). PVDF membranes were blocked in 5% non-fat dry milk in TBST and incubated with an anti-MDR1 mouse monoclonal antibody (C219 clone, 1:500, ID Labs Biotechnology, Inc., London, ON), anti-MRP2 mouse monoclonal antibody (M2 III-6 clone, 1:100, Abcam, Inc., Cambridge, MA) or anti-BCRP rat monoclonal antibody (BXP-53 clone, 1:50, Abcam, Inc., Cambridge, MA) in 2% non-fat dry milk TBST. These MDR1, MRP2, and BCRP antibodies are commercially available and produce distinct, quantifiable bands when used as described in the next paragraph (data S2). Furthermore, they have previously been utilized to analyze the expression of transporters in both human and animal tissues [19,20,21].

---

**Table 1. Inclusion/exclusion criteria.**

| Group   | Inclusion criteria                                      | Exclusion criteria                                                                 |
|---------|--------------------------------------------------------|-----------------------------------------------------------------------------------|
| Term control | • >37 weeks + 0 days                                   | • Pertaining to diabetes status:  
  - T1DM, T2DM, or GDM  
  • Other:  
    - Hypothyroidism or hyperthyroidism  
    - Cushing’s disease  
    - Essential hypertension  
    - Pregnancy-induced hypertension  
    - Rheumatic fever  
    - Thalassemia  
    - Sickle cell anemia  
    - von Willebrand disease  
    - Immunothrombocytopenia  
    - Multiple sclerosis  
    - Epilepsy  
    - Bipolar (medicated)  
    - Systemic lupus erythematosus  
    - Antiphospholipid antibody syndrome  
    - Rheumatoid arthritis  
    - Inflammatory bowel disease  
    - Irritable bowel syndrome  
    - Chorioamnionitis  
    - Group B streptococcus  
    - Sexually transmitted infections  
    - Urinary tract infections  
    - H1N1 during pregnancy  
    - Gallstones or kidney stones  
    - Renal or liver disease  
    - Cholestasis of pregnancy  
    - Placenta increta/percreta  
    - Placental abruption  
    - Pelvic inflammatory disease  
    - Recovered from cancer  
    - Smoking during pregnancy  |
| T1DM-I  | • T1DM (insulin-managed)  
  • >37 weeks + 0 days | • Pertaining to diabetes status:  
  - T2DM  
  • Other:  
    - Same as term control group  |
| GDM-I   | • GDM (insulin-managed)  
  • >37 weeks + 0 days | • Pertaining to diabetes status:  
  - T1DM, T2DM, GDM (diet-managed)  
  • Other:  
    - Same as term control group  |

doi:10.1371/journal.pone.0035027.t001
After a series of washes with TBST, membranes were incubated with a horseradish peroxidase-labeled secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in 2% non-fat milk TBST. Following a series of washes with TBST, immunoreactive proteins were detected in membranes using ECL Plus chemiluminescence (Amersham Biosciences, Baie d’Urfe, QC). The optical density (OD) of each band was determined using ImageJ for Macintosh (version 1.44o) software. To confirm equivalent protein loading, immunodetection using an anti-β-actin monoclonal antibody was employed (AC-15, 1:30,000, Sigma-Aldrich, Oakville, ON) so that the OD of MDR1, MRP2 and BCRP could be normalized internally to β-actin. To correct for gel-to-gel variability, a calibrator sample was run in each gel. Protein-of-interest/β-actin ratios for each blot were converted to percentages of that blot’s calibrator sample’s ratio.

Statistics

Patient and transporter expression data were analyzed using GraphPad Prism 5.0 for Macintosh (GraphPad Software, Inc., San Diego, CA). Patient clinical characteristics were all analyzed using the ANOVA followed by the post hoc Bonferroni’s multiple comparison test to assess for subgroup differences. Western blot and quantitative real-time PCR results are reported as protein (or gene)-of-interest/β-actin ratio as % calibrator for each placental group. Protein (or gene)-of-interest/β-actin ratio as % calibrators were compared by ANOVA followed by the post hoc Dunn’s or Bonferroni’s multiple comparison test to assess for subgroup changes in protein and mRNA expression. Spearman coefficient analysis was used to determine the correlation between the levels of mRNA and protein expression of MDR1, MRP2, and BCRP transporters to HbA1c levels. Power analysis was performed using G*Power 3.1 for Macintosh [22]. Levels of significance for statistical analyses were set at or below α = 0.05, indicated as follows: *, p<0.05 and **/#, p<0.01. All results are presented as mean±S.D.

Results and Discussion

There are a number of short- and long-term maternal and fetal consequences of unmanaged, or poorly managed, diabetes in pregnancy. Throughout gestation, pregnant women with diabetes
can experience polyuria, polydipsia and hyperphagia (the classical triad of diabetes symptoms). Pregnant women with diabetes can also experience hyperlipidemia [23,24,25,26] and reduced weight gain [27]. For the fetus, in the prenatal period, there is increased production of fetal insulin, which leads to increased storage of excess glucose as fetal adipose tissue and the development of macrosomia [28,29]. Placental enlargement is also a feature of pregnancies affected by diabetes [30,31,32,33,34,35,36]. With T1DM, shorter gestational periods have been reported [33]. The long-term consequences of unmanaged, or poorly managed, diabetes in pregnancy revolve primarily around the risk of future metabolic disease in both mother, when GDM, and child [28,29,37,38]. These consequences, both short- and long-term, are believed to be directly related to the degree of maternal hyperglycemia (i.e., the severity of maternal disease across gestation).

Patient data for the groups with diabetes indicate that only the T1DM-I group displayed characteristics of poorly managed diabetic pregnancy (Table 2; data S1). In the T1DM-I group, gestation was significantly shorter ($p<0.01$) and there was a trend toward larger placental volume ($p = 0.07$). Despite T1DM mothers having a shorter gestational age, their neonates actually trended towards a higher birth weight (Table 2). It is possible that neonates in this condition would have become significantly heavier had their gestations been of equivalent duration. Nonetheless, the absence of significant differences in neonatal birth weight, particularly given the strong correlation that exists between neonatal birth weight and maternal blood glucose concentrations, could signify adequate glycemic control in this study’s T1DM-I and GDM-I subgroups [39,40].

Following a high fasting blood glucose reading or high oral glucose tolerance test, women are diagnosed with diabetes and their HbA1c levels monitored over time to track glyemic control. In proportion to blood concentrations, glucose is able to react with their HbA1c levels monitored over time to track glyemic control. Mean HbA1c values for both diabetic groups fell within acceptable ranges for managed diabetes (i.e., ≤6.5% HbA1c), which is again supportive of proper glycemic control at the group level. At the individual level, though, 4 diabetic groups fell within acceptable ranges for managed diabetes (i.e., ≤6.5% HbA1c), which is again supportive of proper glycemic control at the group level. At the individual level, though, 4 diabetic groups fell within acceptable ranges for managed diabetes (i.e., ≤6.5% HbA1c), which is again supportive of proper glycemic control at the group level. At the individual level, though, 4 diabetic groups fell within acceptable ranges for managed diabetes (i.e., ≤6.5% HbA1c), which is again supportive of proper glycemic control at the group level.

Table 2. Clinical data.

| Characteristic                      | Control (n = 14) | T1DM (n = 8) | GDM (n = 13) |
|------------------------------------|-----------------|-------------|-------------|
| Age (years)                        | 32±4            | 33±3        | 35±4        |
| Ethnicity                          |                 |             |             |
| Caucasian                          | 11 (79)         | 6 (75)      | 7 (54)      |
| Asian                              | 3 (21)          | 0 (0)       | 1 (8)       |
| Black                              | 0 (0)           | 0 (0)       | 2 (15)      |
| Other                              | 0 (0)           | 2 (25)      | 3 (23)      |
| BMI                                | 23.2±4.5        | 25.9±3.9    | 29±6.6*     |
| Duration of diabetes (years)       | N/A             | 17±9        | <1          |
| HbA1c (%)                          | N/A             | 6.4±0.6     | 6±0.8       |
| Therapeutics used (n)              | 2±1             | 4±2         | 3±1         |
| Gravidity (n)                      | 2.3±1.1         | 3.2±2.2     | 2.2±0.9     |
| Parity (n)                         | 1.8±0.8         | 2.1±1.2     | 1.8±0.7     |
| Gravidity/parity ratio             | 1.3±0.6         | 1.6±0.4     | 1.2±0.3     |
| GBS status                         |                 |             |             |
| Positive                           | 0 (0)           | 0 (0)       | 0 (0)       |
| Negative                           | 14 (100)        | 8 (100)     | 8 (69)      |
| Unknown                            | 0 (0)           | 0 (0)       | 4 (31)      |
| Mode of delivery                   |                 |             |             |
| Vaginal                            | 5 (36)          | 4 (50)      | 2 (15)      |
| C-section                          | 9 (64)          | 4 (50)      | 11 (85)     |
| Rupture of membranes               |                 |             |             |
| SROM                               | 3 (21)          | 2 (25)      | 1 (8)       |
| AROM                               | 11 (79)         | 6 (75)      | 12 (92)     |
| Gestational age (days)             | 275±7           | 266±6**     | 271±5       |
| Neonatal birth weight (g)          | 3481±417        | 3705±542    | 3301±404    |
| Neonatal sex                       |                 |             |             |
| Male                               | 7 (50)          | 6 (75)      | 5 (38)      |
| Female                             | 7 (50)          | 2 (25)      | 8 (62)      |
| Placental weight (g)               | 608±127         | 666±101     | 661±175     |
| Placental volume (cm$^3$)          | 681±174         | 977±381     | 766±283     |
| Neonatal placenta weight ratio     | 5.9±0.8         | 5.4±0.9     | 5.2±1.1     |

Statistical results are presented as mean±SD. All other results are presented as [n (%)]

*Significantly different from term controls (*, p<0.05; **, p<0.01). N/A, not applicable or not available.

*HbA1c values were measured in the 2nd and/or 3rd trimester and are presented as group means, based on 1–5 individual measurements.

Includes drugs, vaccines and vitamin supplements.

Wet, untrimmed weight.

doi:10.1371/journal.pone.0035027.t002

MRD1 mRNA in GDM-I, is consistent with our observations in insulin-managed rat dams with streptozotocin-induced GDM [16]. Interestingly, when examining individual rather than mean levels, plasma HbA1c levels were found to positively correlate with BCRP mRNA ($r = 0.58$, $p<0.01$; Fig. 2D) and protein ($r = 0.45$, $p<0.05$; Fig. 3D) expression in both insulin-managed diabetes groups. Significant correlations were not seen with MDR1 and MRP2 mRNA or protein expression. The strong relationship between glyemic control and BCRP expression in pregnancies complicated by insulin-managed diabetes may indicate that placental BCRP is particularly responsive to periods of hyperglycemia. Future mechanistic studies will follow up on this hypothesis.
BCRP’s substrates are known to include many glucuronide and sulfate conjugates, antineoplastics, antibiotics, antiretrovirals, oral hypoglycemic agents, statins, natural health products, and several dietary carcinogens [43,44,45,46,47,48].

The concept of glucose mismanagement during insulin-managed GDM or T1DM pregnancies has not been well investigated in the literature. To treat diabetes mellitus in pregnancy, exogenous insulin injections are typically self-administered and supplementary insulin tables are used to adjust dosages to meet specific blood glucose goals of individual patients across gestation. Given that many of the women in our study were experiencing diabetes for the first time (i.e. GDM) and that glucose levels and demands can change rapidly over gestation, the regular administration of parenteral insulin in combination may have resulted in patient failures in management of hyperglycemia. Clinical statistics for diabetes mismanagement are limited in pregnancy; however, reports in the literature illustrate that the percentage of patients with GDM who do not achieve their specific blood glucose goals falls between 20–30% [49,50]. In the context of our study, we observed 6 of the 21 women in the combined diabetic groups with HbA1c levels that exceeded 6.5%. This equates to glucose mismanagement of approximately 28% in our clinical population, which is in agreement with the range proposed from Langer’s more powerful studies. Unfortunately, our study lacked statistical power to determine whether women with higher HbA1c levels, who are presumed to have had poorer glycemic control, also had statistically higher levels of BCRP mRNA and protein.

Using animal model-derived effect sizes of 0.78 for Mdr1 (200% mRNA increase, CV = 42%), 0.53 for Mrp2 (456% mRNA increase, CV = 120%) and 0.67 for Bcrp (230% mRNA increase, CV = 53%), a total sample size of 39 patients (13/group) would be required to achieve power $0.8 in an F test for all of the transporters examined in this study. The actual power achieved for MDR1, MRP2 and BCRP analyses in this study, based on these animal model-derived effect sizes, was 0.98, 0.77 and 0.93, respectively (group sizes were averaged for these post hoc power calculations); however, clinical effect sizes are often smaller than effect sizes in animal models. Because placental transporter expression data from unmanaged, or poorly managed, diabetes is unavailable, the true effect size is currently unknown.
In addition to exhibiting smaller effect sizes, clinical data is typically more variable than data obtained in animal models. The overall coefficient of variation, a measure of variation about the mean, for MDR1, MRPI and BCRP protein expression in this study was found to be 71%, 61% and 54%, respectively. This is consistent with our animal model data [16] and comparable to other studies of transporter expression in human term placenta [20,51]. Interestingly, interindividual transporter expression variation, as demonstrated in this study, appears to be small in comparison to other tissues. For example, 55-fold, 20.5-fold and 20-fold variation in human hepatic MDR1 has been observed [52,53,54]. Similarly, there are reports of 6-fold and 3-fold variation in human intestinal MDR1 [55,56].

The strengths of our study lie in the novelty of our findings given that placental transporter expression in GDM-I and T1DM-I has yet to be investigated in a clinically relevant population. Also, our retrospective design allowed for “real-world” results allowing for the possibility of patient non-adherence in their insulin dosage regimens. It is highly plausible that in a true prospective research design where clinical data were collected over time, we may not have observed any such effect due to the ethical requirements of medical staff to recommend changes in insulin dosing or to administer a therapeutic alternative to insulin (e.g., oral hypoglycemics) to help better manage blood glucose in non-adherent patients.

Despite the strength of our retrospective BioBank design, there were some limitations to our work. Firstly, the RCWIH BioBank was only able to extract information contained within the patient charts of donors to the BioBank program. This resulted in a lack of all possible clinical data (e.g., lipid profiling) that could have shed additional light on our patient populations. Also, despite observing significant correlations in our groups with the number of samples that were available, additional samples could have been added to further increase the power and magnitude of our study’s findings. Lastly, the fact that HbA1c levels were not available for our term-matched control patients is a limitation of our study but, clinically, an HbA1c assay is not typically ordered for patients with no history of glucose mismanagement. Samples from pregnancies with documented mismanagement of blood glucose were unavailable.

In conclusion, there are two particularly important aspects of this study. First, it suggests that placental transporter expression in well-managed T1DM-I and a GDM-I pregnancy is not significantly different from healthy term controls. However, this may not hold true when hyperglycemia is unmanaged. Supporting this is the observed significant correlation between HbA1c and BCRP mRNA and protein in both insulin-managed diabetes groups. Increased levels of HbA1c were associated with increased levels of BCRP mRNA and protein and could have implications for maternal-fetal disposition of clinically important therapeutics and other xenobiotics. Admittedly, samples from pregnancies with documented mismanagement of blood glucose were unavailable, so it remains unknown if placental transporter expression is normal in T1DM-I and GDM-I because of proper management or because the human and rat placental response differs. Second, this study provides evidence that interindividual variability in placental transporter expression is comparatively less than that observed in other tissues. This suggests that disease-induced transporter expression changes may be easier to detect in the placenta, as seen in the recent work by Mason et al [57]. Future studies investigating the role of maternal disease in determining placental transporter expression will allow for a better understanding of the disposition of drugs and other xenobiotics during diseased-states in pregnancy.

Supporting Information

Data S1 Tables describing key patient variables. In accordance with the recommendations of Nelson and Burton, supplemental tables describing key patient variables were compiled for each of this study’s three groups.

(DOC)

Data S2 Representative western blots. Representative blots showing MRPI, MDR1, BCRP, and β-actin expression in samples from each of this study’s three groups.

(DOC)

Acknowledgments

We thank the donors and the Research Centre for Women’s and Infant’s Health BioBank program of the CIHR Group in Developmental and Fetal Health (CIHR #MGC-13299), the Samuel Lunenfeld Research Institute and the Mount Sinai Hospital/University Health Network Department of Obstetrics and Gynaecology for the human specimens used in this study. We thank Ms. Andrea Burden (University of Toronto) and Mr. Erik Bracciotti (University of Toronto) for assistance.

Author Contributions

Conceived and designed the experiments: GJA AMC MPM. Performed the experiments: GJA AMC. Analyzed the data: GJA AMC. Wrote the paper: GJA AMC MPM.

References

1. Onakoo P, Väänänen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of Type I diabetes—the analysis of data published on incidence trends. Diabetologia 42: 1395–1403.
2. World Health Organization (2011) Fact Sheet No 312: Diabetes. Available: http://www.who.int/mediacentre/factsheets/fs312/en [2011, March 1].
3. Gwilt PR, Nahhas RR, Tracewll WG (1991) The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clinical Pharmacokinet- ics 20: 477–490.
4. Eversen D, Paston J, Keelen J (2006) ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol 290: R1357–1365.
5. St-Pierre M, Serrano M, Macias R, Dubs U, Hoechli M, et al. (2000) Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279: R1495–1503.
6. Jonker J, Smit J, Brinkhuizen R, Mallepaard M, Beijnen J, et al. (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92: 1653–1656.
7. Ceccova M, Libra A, Pavek P, Nachtigal P, Brabc M, et al. (2006) Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33: 58–65.
8. Lankas G, Wise L, Cartwright M, Pippert T, Umbenhauer D (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12: 457–463.
9. Smit JW, Huisman MT, van Tellingen O, Wilshire HR, Schinkel AH (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104: 1441–1447.
10. Zhou L, Narahariessi S, Wang H, Unadkat J, Hebert M, et al. (2007) The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse - an OPRU Network and UW SCOR study. Mol Pharmacol 73: 949–959.
11. Greedler C, Anger G, Piquette-Miller M, Korin G (2008) Breast cancer resistance protein: Mediating the trans-placental transfer of glyburide across the human placenta. Placenta 29: 39–43.
12. Moisa M, Heikkinen T, Hakola J, Hakala K, Wallerman O, et al. (2005) Functional role of P-glycoprotein in the human blood-placental barrier. Clinical Pharmacology and Therapeutics 78: 123–131.
Placental ABC Transporters in Diabetic Pregnancy

13. Polles E, Lubetsky A, Koren G (2008) The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29: 743–747.

14. May K, Minarkova V, Linnemann K, Zygmunt M, Kroemer HK, et al. (2008) Role of the multidrug transporter proteins ABCB1 and ABCG2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Diops 36: 740–744.

15. Jaeggi ET, Carvalho JS, De Groot E, Api O, Chur S-AB, et al. (2011) Mechanisms of reduced maternal and fetal lipoprotein exposure in a rat model of gestational diabetes. Drug Metab Diops 39: 1850–1859.

16. Nelson DM, Burton GJ (2011) A technical note to improve the reporting of studies of the human placenta. Placenta 32: 193–196.

17. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.

18. Silverman BL, Metzger BE, Cho NH, Loeb CA (1995) Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal maternal adaptations to pregnancy. Williams Obstetrics. 21 ed: McGraw-Hill.

19. Kucuk M, Doymaz F (2009) Placental weight and placental weight-to-birth weight ratio are increased in diet- and exercise-treated gestational diabetes mellitus subjects but not in subjects with one abnormal value on 100-g oral glucose tolerance test. J Diabetes Complicat 23: 25–31.

20. Kim C, Newton KM, Knopp RH (2002) Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25: 1862–1868.

21. Kiviranta M, Kajanne A, Kivistö T, Sistonen H, et al. (2008) The role of P-glycoprotein in the placental transport of drugs. Clin Pharmacol Ther 84: 256–265.

22. Simonsen SE, Kehlet F, Poulsen A (2007) The role of ABC transporters in the placenta. Am J Obstet Gynecol 196: 104.e1–104.e12.

23. Bajaj SC, Jhingran A, Nair S, John R, et al. (2008) Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 337: a1680.

24. Pavek P, Merino G, Wagenaar E, Blescher E, Novotna M, et al. (2005) Human breast cancer resistance protein: interactions with steroidal drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, and transport of conivaptan. J Pharmaco Exp Ther 312: 144–152.

25. May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, et al. (2008) Role of the multidrug transporter proteins ABCB1 and ABCG2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Diops 36: 740–744.

26. Knopp RH, Warth MR, Charles D, Childs M, Li JR, et al. (1986) Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes. Clin Res 25: 126A.

27. Couch SC, Philipson EH, Bendel RB, Pujda LM, Milvae RA, et al. (1998) Placental lipoprotein changes in gestational diabetes mellitus: a cross-sectional and prospective study. J Clin Pathol 49: 634–637.

28. Zamek-Gliszczynski MJ, Nezasa K-I, Tian X, Kalvass JC, Patel NJ, et al. (2006) The important role of Bcrp (Abcg2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Diops 35: 1873–1879.

29. Pollex E, Lubetsky A, Merino G, Milvae RA, et al. (2008) The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29: 743–747.

30. Bajaj SC, Jhingran A, Nair S, John R, et al. (2008) Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 337: a1680.

31. Kiviranta M, Kajanne A, Kivistö T, Sistonen H, et al. (2008) The role of P-glycoprotein in the placental transport of drugs. Am J Obstet Gynecol 196: 104.e1–104.e12.

32. Bajaj SC, Jhingran A, Nair S, John R, et al. (2008) Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 337: a1680.

33. Kim C, Newton KM, Knopp RH (2002) Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25: 1862–1868.

34. Kiviranta M, Kajanne A, Kivistö T, Sistonen H, et al. (2008) The role of P-glycoprotein in the placental transport of drugs. Am J Obstet Gynecol 196: 104.e1–104.e12.

35. May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, et al. (2008) Role of the multidrug transporter proteins ABCB1 and ABCG2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Diops 36: 740–744.

36. Knopp RH, Warth MR, Charles D, Childs M, Li JR, et al. (1986) Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes. Clin Res 25: 126A.

37. Zamek-Gliszczynski MJ, Nezasa K-I, Tian X, Kalvass JC, Patel NJ, et al. (2006) The important role of Bcrp (Abcg2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Diops 35: 1873–1879.

38. Pollex E, Lubetsky A, Merino G, Milvae RA, et al. (2008) The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29: 743–747.

39. Kiviranta M, Kajanne A, Kivistö T, Sistonen H, et al. (2008) The role of P-glycoprotein in the placental transport of drugs. Am J Obstet Gynecol 196: 104.e1–104.e12.

40. Bajaj SC, Jhingran A, Nair S, John R, et al. (2008) Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 337: a1680.